BALTIMORE, MD -- (Marketwired) -- 07/08/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that the medical marijuana industry received a major boost at the recently concluded annual United States Conference of Mayors. At the event, a unanimous and bipartisan resolution urging the federal government to let states decide for themselves how to handle marijuana policy passed with no speakers rising in opposition. This news, on the heels of New Hampshire becoming the final state in New England to approve a medical marijuana program, serves only to benefit entities engaged in medical marijuana research such as Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB: NVLX).
Moreover, a series of independent polls over the past few months indicate a disconnect between most U.S. citizens, physicians, and state legislators, and the federal government regarding medical marijuana. For example, a Fox News poll found that 85% of Americans support medical marijuana usage if prescribed by a doctor and 75% of doctors surveyed in a New England Journal of Medicine poll conveyed similar sentiments. This disconnect is even more apparent if one considers that the U.S. Government, through the Health and Human Services division, was granted a patent (#633507) titled "Cannabinoids as Antioxidants and Neuroprotectants" that concerns the use of components of medical marijuana for the treatment of neurologic, and other, disorders.
This groundswell of support will eventually lead to the re-classification or downgrade of cannabis from Schedule I of the Controlled Substances Act of 1970 and the greater availability of research grade quantities of marijuana. A change in classification would provide a huge boost to the entire medical marijuana industry as the current category classifies it as a drug with no medicinal value and high potential for abuse, despite the fact that prescription drugs kill more Americans than even hardcore drugs such as heroin and cocaine combined.
As broad, vocal support grows and favorable state legislation continues, the industry is likely to reach a major inflection point as early as 2014. These events will aid in Nuvilex's formative stages of studying the effect of cannabidiol (CBD)-based cancer treatments (CBD is one of the components of marijuana that are collectively known as cannabinoids) when combined with highly efficacious live-cell encapsulation-based therapies similar to those that have been used for oncologic diseases such as inoperable pancreatic cancer and breast cancer. Nuvilex's combination CBD-based cancer studies with live-cell encapsulation therapy development might result in bringing a highly effective product and new delivery system for use to treat multiple diseases and conditions, which would place Nuvilex near the head of the medical marijuana product development class.
A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.
Goldman Small Cap Research
Most Popular Stories
- NSA Defends Global Cellphone Tracking Legality
- Top Websites for U.S. Hispanics
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- Apple Wants Samsung to Pay $22M for Patent Dispute Legal Bills
- Starbucks Gets Grinchy; No Gingerbread Lattes for Tampa Customers
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Jobs Report Brings Cheer As Unemployment Drops to Five-year Low
- Apple Paid Its Lawyers More Than $60MM to Defeat Samsung in Court
- US Consumer Borrowing Rose $18.2B in Oct.